ClinicalTrials.gg
RecruitingNCT07570459CMT-TREMUpdated May 6, 2026

TREMOR IN CHARCOT-MARIE-TOOTH

An observational study in CMT, CMT (Charcot Marie Tooth Disease) and Charcot Marie Tooth Disease (CMT), sponsored by University Medical Center Goettingen. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by University Medical Center Goettingen · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
75
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Tremor is a symptom that has already been described in many case reports and case series concerning patients with Charcot-Marie-Tooth (CMT) disease. However, the pathophysiology of tremor in this condition remains largely unclear. It has also not been sufficiently investigated to what extent tremor in CMT patients constitutes a relevant impairment of quality of life.

This project focuses on a more detailed characterization of tremor in CMT patients using surface electromyography and accelerometer analysis, as well as the collection of individual clinical data, particularly regarding the symptom of tremor, in order to facilitate the characterization and etiological classification of the tremor. In addition, a questionnaire-based assessment will be conducted to capture the impact of tremor on activities of daily living and the associated burden in this specific patient cohort.

The entire data collection process will be supported by a clinical examination, which will be video-recorded by experienced neurologists to ensure more reliable analysis. This serves both the characterization of tremor and the illustration of its functional limitations. Where available, the data will be correlated with genetic variants to allow conclusions about possible genetic predispositions or disease progression. As a control group, CMT patients who have not yet reported a tremor will be included.

02

Conditions studied

  • CMT
  • CMT (Charcot Marie Tooth Disease)
  • Charcot Marie Tooth Disease (CMT)
  • Charcot Marie Tooth Disease

Keywords

  • Tremor in CMT
03

In context

Charcot-Marie-Tooth Disease

115 studies on the registry are indexed under Charcot-Marie-Tooth Disease; 39 are open to participants now.

This study's planned enrollment of 75 is below the median of 120 across 49 observational studies indexed under Charcot-Marie-Tooth Disease.

Browse Charcot-Marie-Tooth Disease studies →

Lead sponsor

University Medical Center Goettingen is the lead sponsor of 62 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

CMT-patients and healthy controls

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical CMT Diagnosis / Anamnestically Healthy Control Group
  • Genetic confirmation of CMT in adult patients
  • Ability to achieve the outcome measure at baseline
  • Age between 18 and 65 years
  • Capacity of all study participants to consent and signed , including patient or participant information and consent form

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding period
  • Other relevant neurological or psychiatric disorders, acute or in the past history
  • Presence of a serious previous internal disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • CMT patients
  • Controls
06

What researchers measure

Primary outcomes

  1. Activities of Daily Living -Questionaire(ADL)

    Time frame: baseline

  2. Assessment of Handicap - Questionaire

    Time frame: baseline

  3. Fahn Tolosa Marin Rating Scale

    Time frame: baseline

  4. Electrophysiological characterization of tremor using surface EMG and accelerometer analysis

    Time frame: baseline

Secondary outcomes

  1. MDS-UPDRS Part III without Tremor

    Time frame: baseline

  2. SARA Score

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
  • University Medical Centre
    Göttingen, Lower Saxony 37075, Germany
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
May 6, 2026
StartActual
Jul 30, 2024
Primary completionEst.
Jul 5, 2026
CompletionEst.
Oct 30, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07570459
Lead sponsor
University Medical Center Goettingen
Responsible party
Michael W Sereda, MD, Professor of Neurology (Prof. Michael Sereda MD, University Medical Center Goettingen) — Principal investigator
First posted
May 6, 2026
Start date
Jul 30, 2024
Primary completion
Jul 5, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
May 6, 2026

Study contacts

Michael W Sereda, Prof. MD
Contact
sereda@mpinat.mpg.de
+49 551 3964162

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion